Trial reportCalcified tissue international1996
Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Trial report in Calcified tissue international, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 104 citations in OpenAlex.
- Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2007Trial
- The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2006Trial
- Trial
- Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management.JBJS reviews · 2026Review
- Chronic salmon calcitonin exerts an antidepressant effectFrontiers in molecular neuroscience · 2023Article
- The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats.International journal of nanomedicine · 2023Article
- The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.Drugs · 2021Review
- Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density.Iranian Red Crescent medical journal · 2015Article
- Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2012Article
- Complexation Hydrogels for the Oral Delivery of Growth Hormone and Salmon Calcitonin.Industrial & engineering chemistry research · 2010Article
- Impact of Absorption and Transport on Intelligent Therapeutics and Nano-scale Delivery of Protein Therapeutic Agents.Chemical engineering science · 2009Article
- Progress in osteoporosis and fracture prevention: focus on postmenopausal women.Arthritis research & therapy · 2009Review
- Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.Pharmacy world & science : PWS · 2005Article
- The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.Drugs & aging · 2004Review
- 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002Review
- Rheumatology: 15. Osteoporosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2001Article
- Nasal calcitonin.Endocrine · 1997Review
- Calcitonin in the treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997Review
- Salmon calcitonin nasal spray : An effective alternative to estrogen therapy in select postmenopausal women.Endocrine · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover over a period of 2 years. Our study comprised 117 Caucasian postmenopausal women, otherwise healthy apart from reduced bone density. They received either intranasal synthetic SCT (200 IU either three times weekly or daily) or placebo. Compared with placebo, daily intranasal calcitonin resulted in no significant bone loss in the lumbar spine, as assessed by dual photon absorptiometry, over the 2-year study period (P < 0.02). In this group, women more than 5 years postmenopause, with the lowest baseline bone mass, showed the greatest response to this treatment, with a total increase placebo in lumbar spine BMD of 3.1%. Significant spinal bone loss (P < 0.005) occurred in women receiving either placebo or thrice-weekly calcitonin. Although the rates of bone loss in the proximal femur were not significantly different in the three groups, there were differences over time. Whereas bone loss in the daily calcitonin group was insignificant, women who received placebo or thrice-weekly calcitonin experienced significant bone loss (P < 0. 001). No significant changes in biochemical markers were observed in any group. Therapy was well tolerated and there were no significant treatment-related adverse events. We conclude that intranasal SCT 200 IU daily is effective and safe for the prevention of bone loss in postmenopausal women with reduced bone mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.